Orient Europharma Co

Orient Europharma Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Orient Europharma Co (4120.TWO) as of Oct 18, 2026 is 84.75 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 77.94 % — a change of 8.73% (higher).

FCF Conversion

84.75 %

YoY

8.73%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Orient Europharma Co is 2025 84.75 % . FCF Conversion Rate (FCF/EBITDA) of Orient Europharma Co was 2024 77.94 % . It decreases by 8.73% higher compared to the previous year.

The Orient Europharma Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
12.04 TWD
Jan 1, 2019
41.34 TWD
Jan 1, 2020
188.54 TWD
Jan 1, 2021
-1,235.85 TWD
Jan 1, 2022
276.03 TWD
Jan 1, 2023
-25.03 TWD
Jan 1, 2024
77.94 TWD
Jan 1, 2025
84.75 TWD
The Orient Europharma Co FCF Conversion history
YEARFCF ConversionYoY
84.75 %+8.73%
77.94 %-411.43%
-25.03 %-109.07%
276.03 %-122.34%
-1,235.85 %-755.48%
188.54 %+356.05%
41.34 %+243.41%
12.04 %-76.34%
50.88 %-310.40%
-24.18 %-113.02%
185.71 %+131.88%
80.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Orient Europharma Co Stock analysis

What does Orient Europharma Co do? Orient Europharma Co Ltd, based in Taipei City, Taiwan, operates in the Health Care sector, specifically within Pharmaceuticals. The company manufactures and trades western medicine, health food, and cosmetics, with a focus on nutritious healthcare products, medical cosmetic products, and western drugs. Its product segments include infant milk powders, functional healthcare items, dermatological preparations, medical hair care, organic skincare, and pharmaceuticals for conditions such as cardiovascular diseases, cancer, and diabetes. Listed on 28 November 2002. Orient Europharma Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Europharma Co stock

FCF Conversion Rate (FCF/EBITDA) of Orient Europharma Co is 84.75 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Orient Europharma Co changed from 77.94 % to 84.75 %, representing a 8.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Orient Europharma Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Orient Europharma Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Orient Europharma Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Orient Europharma Co